Companies /Healthcare

Gilead Sciences Inc

NASDAQ: GILD Drug Manufacturers - General
$148.09
▼ $0.68 (−0.46%) today
Markets closed · 12:02am ET

GILD Coverage

Page 32
8:05am ET
Health and Healthcare

Short Sellers Increase Bets in Major Biotech

The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.

Chris Lange
10:50am ET
Health and Healthcare

Biogen Follows Gilead With Large Debt Offering

ThinkstockAre biotech companies going to become the next big companies saddled with debt? Most likely not, but two debt offerings will stand out to investors here. The first was a $10 billion…

Jon C. Ogg
1:27pm ET
Health and Healthcare

Should Gilead Really Be Rated Underperform?

ThinkstockMost analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis C vaccines (HCV) Harvoni and Solvaldi. For the most part the resulting…

Chris Lange
4:54pm ET
Health and Healthcare

Gilead Tops Estimates in 2Q

courtesy of Gilead SciencesGilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results Tuesday after the markets closed. The biotech giant had $3.15 in earnings per share (EPS) on $8.2 billion in revenue…

Chris Lange
7:57am ET
Health and Healthcare

Short Sellers Back Off Major Biotechs

ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or…

Chris Lange